Overview

Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine - Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Collaborator:
Merck Serono International SA
Treatments:
Cetuximab
Gemcitabine
Oxaliplatin